-
MTT Workflow for Cell Viability and Differentiation
2026-10-01
Build a reproducible MTT workflow for metabolic activity measurement, cytotoxicity testing, and differentiation studies. The approach translates findings from a rat dental follicle cell model into practical controls, optimization steps, and decision points for broader in vitro research.
-
(S,S)-Nanaomycin A for NEPC Research
2026-09-30
Use (S,S)-Nanaomycin A to test whether DNMT3B activity sustains neuroendocrine prostate cancer growth and lineage plasticity. This workflow pairs dose-response pharmacology with genetic controls, lineage-marker profiling, apoptosis measurements, and tumor-model validation.
-
Verapamil as a Hypoxia-Inflammation Probe
2026-09-30
Verapamil ((±)-Verapamil) can reveal how hypoxia duration shapes urothelial inflammatory signaling. This article focuses on assay interpretation, causal controls, and the limitations of using a multifunctional calcium channel and P-glycoprotein inhibitor to interrogate the ROS/TXNIP/NLRP3 axis.
-
Cyclosporin A (B1922): Practical Assay Guide
2026-09-29
Cyclosporin A (B1922), also called cyclosporine, provides a controlled cyclophilin and calcineurin-NFAT pathway perturbation for cell and selected animal research. It is suitable for autoimmune disorder research, apoptosis modulation, and mitochondrial injury workflows, but its water insolubility and short-term solution-storage guidance make it unsuitable for experiments requiring aqueous preparation or prolonged storage of working solutions.
-
Dabigatran: Clinical and Pharmacoeconomic Evidence
2026-09-29
This review established an early clinical and economic framework for evaluating dabigatran, the first commercially available oral direct thrombin inhibitor, across atrial fibrillation, venous thromboembolism, and orthopedic prophylaxis. Its central contribution was to balance favorable efficacy and reduced monitoring against bleeding, renal accumulation, treatment discontinuation, cost, and limited long-term evidence.
-
Allosteric Control of Cas13d by Domain Insertion
2026-09-28
This study engineers RfxCas13d activity by inserting regulatory domains at an allosteric hotspot, producing variants controlled by blue light or rapamycin analogs. The single-protein designs enable stimulus-dependent RNA knockdown and offer an alternative to split Cas13 systems, although further testing is needed to establish their performance across targets and biological contexts.
-
LGK-974: A PORCN Inhibitor Workflow for Wnt Research
2026-09-27
LGK-974 enables researchers to test whether Wnt-dependent phenotypes rely on PORCN-mediated ligand secretion, with practical starting conditions for cell and co-culture assays. This guide connects developmental patterning insights to cancer-model experiments while clarifying what the reference study does—and does not—establish about the compound.
-
From CB2 Pharmacology to Metastasis Signaling
2026-09-26
Tetrahydromagnolol offers a defined pharmacological tool for peripheral CB2 receptor studies. This article connects its established receptor profile with a separate GPCR-to-cytoskeleton finding in triple-negative breast cancer, and lays out a cautious experimental strategy for testing—rather than assuming—whether these signaling questions intersect.
-
Resiquimod in Tumor Ablation: From Signal to Strategy
2026-09-26
Thermal ablation can leave a difficult margin: tissue that is not fully destroyed, yet may not generate an effective antitumor response. This article examines how Resiquimod (R-848) provides a mechanistic tool for studying innate immune activation alongside local ablation, and what hydrogel-enabled preclinical findings mean—and do not yet mean—for translational research.
-
EZ Cap EGFP mRNA: A Translational Strategy
2026-09-25
A mechanistic and practical guide to using capped, modified EGFP reporter mRNA to evaluate delivery, translation, and cell responses—while keeping carrier effects and model-specific limitations in view.
-
MK-571 (L-660,711): Beyond Leukotriene Blockade
2026-09-25
MK-571 (L-660,711) is best understood as a dual-purpose research tool: a cysteinyl leukotriene receptor antagonist and an MRP1/ABCC1 inhibitor. This article explains how to distinguish those activities and interpret a macrophage chemoprotection study without over-attributing its results to leukotriene signaling.
-
Eltanexor: Assay Design Beyond Cytotoxicity
2026-09-24
Eltanexor (KPT-8602) is an XPO1 inhibitor whose effects extend beyond cancer-cell viability. This article examines how colorectal cancer findings can guide assay selection, pathway readouts, and careful interpretation of preclinical evidence.
-
Metabolism as a Gatekeeper of Early Embryo Fate
2026-09-24
A WDR36 study connects glycolytic metabolism with trophectoderm commitment in human blastoid models. Here, we examine what the findings mean for translational study design, where the evidence stops, and how to use recombinant reagents responsibly in adjacent research questions.
-
EdU Imaging Kits (HF594): Practical Protocol
2026-09-23
EdU Imaging Kits (HF594), SKU K2243, provide a click-chemistry workflow for measuring DNA synthesis during S phase by fluorescence microscopy or flow cytometry. They are appropriate for cell proliferation and cell-cycle assays, but EdU incorporation alone should not be interpreted as proof of completed cell division, viability, or a specific biological mechanism.
-
Morin and Podocyte Mitochondrial Energy Metabolism
2026-09-22
A 2025 study identifies AMPD activity in the purine nucleotide cycle as a mechanistic link between high-fructose exposure, podocyte mitochondrial dysfunction, and glomerular injury. Its combination of animal phenotyping, podocyte bioenergetics, molecular docking, and AMPD2 knockdown positions Morin as a tool for studying energy-metabolism-driven kidney injury rather than only as a general antioxidant.